**Abstract.** – BACKGROUND: Hepatic fibrosis is characterised by a progressive accumulation of fibrillar extracellular matrix (ECM) proteins, including collagen that occurs in chronic liver diseases. Transforming growth factor-beta1 (TGF-beta1)/Smad3 signalling plays a major role in tissue fibrogenesis acting as a potent stimulus of ECM accumulation.

AIM: To evaluate the effects of a combined therapy with anti-inflammatory *Boswellia* and anti-fibrotic *Salvia* extracts on the course of chronic hepatitis-associated fibrosis induced by dimethylnitrosamine (DMN) in mice, as well as on the hepatic expression of TGF-beta1 and Smad proteins.

METHODS: Chronic hepatitis-associated fibrosis was induced in mice by intraperitoneal DMN administration. Mice were assigned to 5 groups: controls; DMN without any treatment; DMN treated orally with *Boswellia* extracts (50 mg/kg/day); DMN treated orally with *Salvia* extracts (150 mg/kg/day); DMN treated orally with both *Boswellia* (50 mg/kg/day) and *Salvia* extracts (150 mg/kg/day). The liver was excised for macroscopic examination and histological, morphometric and immunohistochemical (IHC) analyses. For IHC, alpha-smooth muscle actin (alpha-SMA), collagen types I-III, TGF-beta1, connective tissue growth factor (CTGF), Smad3, Smad7, CD3, PCNA and TUNEL antibodies were used.

RESULTS: The combined oral administration of *Boswellia* and *Salvia* extracts improved the course and macroscopic findings of DMN-induced chronic hepatitis in mice, as well as on the hepatic expression of TGF-beta1 and Smad proteins.

CONCLUSIONS: These data demonstrate that co-treatment of *Boswellia* plus *Salvia* extracts is effective in preventing hepatic fibrosis in DMN-induced chronic hepatitis. The anti-fibrotic properties are mainly related to *Salvia* extracts and appear to be mediated by the inhibition of the TGF-beta1/Smad3 pathway.

**Key Words:**

**Introduction**

Hepatic fibrosis is characterised by a progressive accumulation of fibrillar extracellular matrix (ECM) proteins, mainly collagen, that occurs in response to a variety of insults, including viral hepatitis, alcohol abuse, drug use, metabolic disease, autoimmune disease. Fibrosis is a chronic and progressive process regulated by a complex system of cell/matrix/cytokine and growth factors, but it may be a reversible event. The physiological fibrogenesis process triggered by the onset of inflammation may lead to tissue repair or to fibrosis depending on the balance between extracellular matrix (ECM) synthesis or degradation. ECM degradation is mediated by the metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The pathological fibrosis leads to a progressive deterioration of the organ-specific function.

During liver injury, hepatic stellate cells (HSCs), a major fibrogenic liver cell type, are activated and transdifferentiated to become myofibroblasts (MFBS). MFBS proliferate and acquire fibrogenetic characteristics, such as expression of alpha-smooth muscle actin (alpha-SMA) as well as synthesis and secretion of ECM proteins, in particular type I and type III collagen. During hepatic fibrogenesis, HSCs are activated by several inflammatory cytokines and growth factors. Of these, transforming growth factor-beta (TGF-beta) seems to be the most important fibrogenic factor for MFBS. TGF-beta, via intracellular...
lar TGF-β/Smad signalling pathway, is recognized as the strongest factor inducing ECM deposition by simultaneously stimulating the synthesis of new matrix components, increasing the synthesis of enzymes that inhibit ECM degradation, and decreasing the synthesis of matrix-degrading proteases.

Several anti-fibrotic drugs (chemical and biological) have been tested in experimental models of tissue fibrosis and shown to inhibit, mitigate or even reverse the fibrogenesis/fibrosis process. Their anti-fibrotic activity would appear to be related to various mechanisms of action, by reducing activated ECM-producing cells and their profibrogenic effects (proliferation, motility, contraction, ECM deposition), by promoting ECM-producing cells apoptosis, or by promoting ECM degradation. Not only the efficacy, but also the safety of the anti-fibrotic drugs is important as these have to be administered for a prolonged period of time. Numerous pharmaceutical agents have been experimented with varying degrees of success, but with unacceptable side-effects in long-term treatment. Therefore, the research of new therapeutic strategies, based on the association of drugs with anti-inflammatory and anti-fibrotic properties, is needed in fibrotic diseases.

Among the numerous drugs investigated so far for their anti-fibrotic potential, botanicals represent a remarkable component. The development of anti-fibrotics from natural products may reduce the risk of toxicity whilst maintaining the therapeutic effectiveness when the drug is used in the clinical setting. Botanical extracts with anti-fibrotic properties have been evaluated both in experimental and clinical studies showing efficacy and safety in many organs.

Of the botanicals, our attention has been focused on *Boswellia Serrata* and *Salvia Miltiorrhiza*. The gum resin extracts from *Boswellia Serrata* have been reported to have an anti-inflammatory and immunomodulatory effect. Boswellic acids, ursane type of pentacyclic triterpenes, have been identified as the main biologically active components of Boswellia extracts.

*Salvia Miltiorrhiza* has been reported to exert inhibitory effects, both in vitro and in vivo, against hepatic fibrosis. *Salvia Miltiorrhiza* has been shown to decrease the production of the ECM components fibronectin, laminin and collagen I and III protein. Several compounds have been extracted and analysed from *Salvia Miltiorrhiza* roots, the most potent of which would appear to be salvianolic acid and Tanshinone II-A.

Aim of the present study was to evaluate: (1) the prophylactic effect of anti-inflammatory *Boswellia* extracts, alone or in combination with anti-fibrotic *Salvia* extracts, on the development of chronic hepatitis-associated fibrosis induced by dimethylnitrosamine (DMN) in mice, and (2) their potential regulatory effects on the pro-fibrotic TGF-β/Smads pathway.

DMN is a potent hepatotoxin and is an established model of liver fibrosis with a pathophysiology closely resembling that of cirrhosis in man. This model has been shown to produce many decompensating features of human hepatic fibrosis, such as portal hypertension, ascites, hypoproteinaemia and biochemical abnormalities. Therefore, it may represent a useful model for screening anti-fibrotic agents.

### Materials and Methods

#### Animals

Forty-six black Swiss 10 week-old mice were used (Charles River Laboratories, Calco, Lecco, Italy). Animals were kept in a restricted-access room with controlled temperature (23°C) and light/dark cycles (12h/12h). Standard rodent chow pellets (Laboratori Piccioni, Gessate, Milan, Italy) and tap water were allowed ad libitum.

The protocol was approved by the Animal Research Committee of the University of L’Aquila, L’Aquila, Italy.

#### Induction of Hepatitis

Chronic hepatitis-associated fibrosis was induced by intra-peritoneal administration of DMN (Sigma Aldrich, Milan, Italy) under light ether anaesthesia. Each mouse received 10 µg DMN per g of body weight (1% in saline solution) for the first 3 consecutive days of the week for 6 weeks. The amount of DMN administered was adjusted each week to body weight. Animals in the control groups received a sham intra-peritoneal injection of the same volume of 0.9% saline.

Animals were monitored daily, for food and fluid intake, and examined for signs of hepatitis, including weight loss and abdominal distension due to ascites, as well as signs of systemic inflammation such as piloerection, lethargy, and perilobular exudates. Animals were weighed at the beginning of the study (pre-treatment), and
thereafter, weekly before each DMN administration. Three days after the last DMN administration (post-treatment), the animals of each group were sacrificed by CO₂ inhalation.

In this protocol, the Authors adhered to the Italian National Research Council criteria for the care and use of laboratory animals.

**Experimental Design**

**Hepatic Fibrosis**

The following 5 groups of mice were included in this study: (1) control mice (control group) (n=6); (2) DMN mice (DMN group) without any treatment (n=10); (3) DMN mice treated orally with Boswellia extracts (50 mg/kg/day) (DMN/Boswellia group) (n=10); (4) DMN mice treated orally with Salvia extracts (150 mg/kg/day) (DMN/Salvia group) (n=10); and (5) DMN mice treated orally with both Boswellia (50 mg/kg/day) and Salvia extracts (150 mg/kg/day) (DMN/Boswellia+Salvia group) (n=10). The dose of Boswellia and Salvia extracts used in the study was similar to that reported by other Authors\(^{20,32-36}\).

As assessed by high performance liquid chromatography, Boswellic powder extracts (Nutraceutica Srl, Monterenzio, Bologna, Italy) are composed of 95% boswellic acids, while Salvia powder extracts (Herbasin Co. Ltd, Shenyang, China) are composed of 40% Tanshinone IIA.

The extracts were dissolved in distilled water according to the established therapeutic dose.

Mice received orally either 0.1 ml of deionized water, Boswellia extracts (50 mg/kg/day) solution, Salvia extracts (150 mg/kg/day) solution or Boswellia plus Salvia extracts solution for a period of 6 weeks.

Mice were weighed once a week to adjust drug dose to body weight. Daily administration started on day 0 and continued for 6 weeks. All the mice were sacrificed 3 days after the last drug administration.

**Sample Recovery and Preparation**

Laparotomy was performed, the liver was visualized and rapidly excised as a whole. The presence of ascites (0=absent, 1=mild, 2=severe) and adhesions between the liver and adjacent organs (0=absent, 1=Mild/focal-zonal, 2=Severe/diffuse) was scored on a 0-2 scale\(^{29}\). The liver was then weighed, and the right lobe was fixed in 10% buffered formaldehyde and embedded in paraffin for histological studies [Haematoxylin and Eosin (H&E), Sirius Red-Fast Green staining and immunohistochemistry].

**Analytical Methods for Serum Samples**

Blood samples were obtained from the inferior vena cava. Serum was collected from blood sample by immediate centrifugation at 10,000 g for 8 minutes at 4°C. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using automated techniques.

**Assessment of Macroscopic and Microscopic Lesions**

Two independent observers, scored the following parameters: liver appearance and colour (0=physiological, 1=pathological without necrosis, 2=pathological with necrosis); liver weight, liver weight/body weight ratio, spleen weight and spleen/body weight ratio\(^{29}\).

Specimens obtained from the right lobe of the liver of all animals were washed and immediately immersed in 10% buffered formalin in phosphate buffered saline (PBS) (pH 7.4) for 3 h at room temperature followed by the standard procedure for paraffin embedding. Serial 3 μm sections were stained with H&E to assess the degree of inflammation and with Sirius Red-Fast Green stain to detect connective tissue and fibrosis. The stained sections were then observed under an Olympus BX51 Light Microscope (Olympus, Optical Co. Ltd., Tokyo, Japan). Two pathologists (A.V. and R.S.), blinded to the study procedures, examined and scored all histological sections of the hepatic samples. Liver fibrosis and necro-inflammatory activity were evaluated semi-quantitatively according to the METAVIR scoring system\(^{37}\). Fibrosis was staged on a 0-4 scale as follows: F0=no fibrosis; F1=portal fibrosis without septa; F2=numerous septa without cirrhosis; F4=cirrhosis. Necro-inflammatory activity was graded as follows: A0 = none; A1 = mild; A2 = moderate; A3 = severe.

**Colorimetric Evaluation of Collagen Content**

Samples (5 mm\(^3\)) of the right lobe of the liver parenchyma, not including the Glisson’s capsule and larger portal branches, were removed and immediately immersed in 10% buffered formalin for paraffin embedding. Eight 15-mm thick, 100 mm\(^2\) large sections were obtained from each liver and used for colorimetric evaluation. Additional 5-mm thick sections were stained and observed.
at light microscopy together with stained sections for colorimetric evaluation according to Lopez-De León and Rojkind\(^8\).

Sections for colorimetric evaluation were deparaffinized through successive baths in absolute toluol, toluol: ethanol (50:50) and 50% aqueous ethanol and water. Staining procedures with fast green FCF 0.1 (Chroma-Gesellscha, no. IA30, Stuttgart, Germany) and Sirius Red F3B 0.01% (Atomergic Chemical Corporation, no. 10022; Plainview, NY, USA) were performed according to Gascon-Barrè et al\(^8\). Colours were eluted in 0.05\(\text{NaOH}\) and 50% aqueous methanol.

The eluted colours were examined in a Lambda 4 B PE spectrophotometer. Correlations between absorbance and protein estimations were assessed according to Gascon-Barrè et al\(^8\).

Non-collagenous protein determination was obtained using the following formula:

\[
\text{Absorbance at } 605 \text{ nm} \times 2.08
\]

\[
\text{Non-collagenous protein (mg)} = \frac{\text{Absorbance at } 605 \text{ nm}}{2.08}
\]

Collagenous protein determination was obtained using the latter interference factor in the following formula:

\[
\text{Collagen (µg)} = \frac{\text{Absorbance at } 540 \text{ nm} - 0.26 \text{ absorbance at } 605 \text{ nm}}{38.4}
\]

Collagen content (collagen/protein ratio) was calculated using the following formula:

\[
\text{Collagen content (µg/mg total protein)} = \frac{\text{µg collagen}}{\text{µg collagen} + \text{mg non-collagenous protein}}
\]

The above mentioned formulae were applied according to Gascon-Barrè et al\(^8\).

**Immunohistochemistry**

Samples from the right lobe of the liver, obtained as described above, were promptly fixed with 10% buffered formalin in PBS (pH 7.4) for 3 h, dehydrated in graded ethanol, and embedded in a low-temperature-fusion paraffin. Serial 3 μm sections were incubated for 40 min in methanol and 3% hydrogen peroxide solution and then rinsed in PBS. Thereafter, sections were incubated overnight at 4°C with polyclonal antibodies to TGF-β1, CD3, α-SMA, collagen I and III, Smad3, Smad7 and CTGF (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), used at a dilution of 1:500, 1:200, 1:500, 1:300+1:300, 1:500, 1:600 and 1:500, respectively, in PBS. Samples were then rinsed with PBS for 5 min and incubated with a labelled streptavidin-biotin-peroxidase conjugate kit (Dako LSAB, cod. K0675, Dako-Cytomation, Milan, Italy). After rinsing in PBS for 10 min, the sections were incubated with 3,3-diaminobenzidine-tetrahydrochloride (DAB, Sigma Aldrich, Milan, Italy) for 1-3 min. For negative controls the primary antibody was replaced (same dilution) with normal serum from the same species.

Finally, the samples were counterstained with Mayer’s Haematoxylin and observed under a photomicroscope (Olympus BX51 Light Microscopy, Olympus, Optical Co. Ltd., Tokyo, Japan). The immunohistochemistry analysis was evaluated using a semi-quantitative score, as previously described\(^4\).

For in situ detection of cell apoptosis, the terminal deoxynucleotidyltransferase-mediated triphosphate end-labelling (TUNEL) method was used (Apoptag kit; Oncor, Gaithersburg, MD, USA).

Cellular proliferation was assessed by proliferating cellular nuclear antigen (PCNA) staining (Dako, PC10; mouse anti-PCNA, used at dilution of 1:100, Dako-Cytomation, Milan, Italy).

**Statistical Analysis**

Data are reported as mean ± standard deviation (SD). For ordinal variables (ascites, liver adhesions, liver colour, degree of fibrosis), results in all groups of mice were analyzed using Kruskal-Wallis non-parametric ANOVA. Post-hoc comparisons between pairs of groups were assessed by using Wilcoxon rank sum test. For quantitative variables (body weight, liver weight, spleen weigh, amino-transferase levels, collagen content), results in all groups of mice were analyzed using one-way parametric ANOVA. A \(p < 0.05\) value was considered to be statistically significant.

Data analysis was performed with SAS, version 9.2, 2008 (SAS Institute, Inc, Cary, NC, USA).

**Results**

**Clinical and Macroscopic Findings**

The effects of Boswellia and Salvia administration and the characteristics of DMN-induced hepatic fibrosis in mice...
Patic fibrosis are outlined in Table I. Age, sex and duration of DMN treatment were comparable in the four groups of mice. The administration of DMN induced weight loss only in the mice of DMN group whereas the groups of mice treated with drugs showed a progressive gain of weight (Figure 1). In particular, mice treated with Salvia alone or in association with Boswellia showed a trend comparable to that of the control group. At the end of the treatment period, DMN-treated mice had a lower body weight compared to control mice (21.60±3.72 and 24.17±6.68, respectively) whereas mice treated with drugs (DMN/ Boswellia, DMN/Salvia and DMN/Boswellia + Salvia) showed a body weight (23.30±4.35, 24.20±5.25 and 24.30±5.21, respectively) comparable to control-group mice (24.17±6.68) (Table I).

Mortality rates in DMN group, DMN/Boswellia group, DMN/Salvia and DMN/Boswellia + Salvia group were 30%, 30%, 10% and 0% respectively.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Controls (n = 6)</th>
<th>DMN (n = 10)</th>
<th>DMN+B (n = 10)</th>
<th>DMN+S (n = 10)</th>
<th>DMN+B+S (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (weeks)</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>4/2</td>
<td>8/2</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>Duration of DMN treatment</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>0</td>
<td>30</td>
<td>30</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>24.17 ± 6.68</td>
<td>21.60 ± 3.72</td>
<td>23.30 ± 4.35</td>
<td>24.20 ± 5.25</td>
<td>24.30 ± 5.21</td>
</tr>
<tr>
<td>Ascites</td>
<td>Np</td>
<td>0.57 ± 0.53*</td>
<td>0.28 ± 0.48</td>
<td>0.11 ± 0.33</td>
<td>Np</td>
</tr>
<tr>
<td>Adhesions</td>
<td>Np</td>
<td>0.42 ± 0.53*</td>
<td>0.28 ± 0.48</td>
<td>Np</td>
<td>Np</td>
</tr>
<tr>
<td>Pathologic colouring</td>
<td>Np</td>
<td>1.28 ± 0.48*</td>
<td>0.85 ± 0.37</td>
<td>0.44 ± 0.52</td>
<td>0.30 ± 0.48</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>1.01 ± 0.34</td>
<td>0.82 ± 0.21</td>
<td>0.89 ± 0.26</td>
<td>0.96 ± 0.22</td>
<td>0.95 ± 0.25</td>
</tr>
<tr>
<td>Liver weight/Body weight ratio</td>
<td>0.041 ± 0.003</td>
<td>0.039 ± 0.013</td>
<td>0.037 ± 0.007</td>
<td>0.040 ± 0.004</td>
<td>0.039 ± 0.004</td>
</tr>
<tr>
<td>Spleen weight (g)</td>
<td>0.10 ± 0.03</td>
<td>0.11 ± 0.02</td>
<td>0.10 ± 0.02</td>
<td>0.10 ± 0.02</td>
<td>0.10 ± 0.03</td>
</tr>
<tr>
<td>Spleen weight/Body weight ratio</td>
<td>0.004 ± 0.001</td>
<td>0.005 ± 0.001</td>
<td>0.004 ± 0.001</td>
<td>0.004 ± 0.001</td>
<td>0.004 ± 0.001</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD; Np = not present; *p < 0.05 vs controls, DMN+S and DMN+B+S.

Figure 1. Body weight gain curves of the 5 groups of mice at basal and weekly, over a 6 weeks treatment. Plot of weight (g) vs age (days). Each point represents mean weight data pooled from 6 controls and 10 treated mice. Standard deviations are indicated. Each point between controls and DMN, as well as between controls and DMN+B, were statistically significant (p < 0.05). Comparing controls versus DMN+S and DMN+B+S, the differences were not statistically significant. DMN = dimethylnitrosamine, B = Boswellia extracts, S = Salvia extracts.
Mild or severe ascites was found in 42.8% of the DMN mice, mild ascites in 28.5% of the DMN/Boswellia mice and in 11% of the DMN/Salvia mice, but was absent in the DMN/Boswellia + Salvia group of mice. Adherences with other organs were present in 42.8% of the DMN mice and in 28.5% of the DMN mice treated with Boswellia alone, but were absent in the DMN mice treated with Salvia alone or in association with Boswellia.

Representative examples of liver taken from each group of mice are shown in Figure 2. The liver of DMN-treated mice was slightly smaller than that of control-mice (0.82±0.21 and 1.01±0.34, respectively), was harder, had a darker colour and a granulose appearance of the surface with the presence, in several cases, of foci of necrosis. The liver of mice treated with Boswellia alone was similar to that of DMN mice and did not show significant differences in the above-mentioned parameters. Instead, livers of mice treated with Salvia alone or in association with Boswellia were similar. In particular, the simultaneous administration of Boswellia and Salvia extracts improved the liver weight, the pathologic colouring, ascites and adhesions (Table I). Liver weight and liver weight/body weight ratio (%), in all groups of mice, are shown in Figure 3.

**Microscopic Findings**

Representative histological findings (H&E and Sirius Red-Fast Green stain) of the liver from controls, DMN mice without any treatment and DMN mice treated with Boswellia plus Salvia extracts, are shown in Figure 4.

A marked increase of connective tissue, in the portal tracts and within the liver parenchyma, was found in mice receiving DMN compared to controls. The liver of DMN/Boswellia + Salvia treated mice presented almost normal parenchymal architecture and mild fibrosis. The degree of hepatic fibrosis was significantly higher in DMN mice compared to controls and the DMN mice treated with Salvia alone and those treated with Boswellia + Salvia (Table II). Likewise, colorimetric evaluation of collagen content demonstrated statistically higher values of collagen in the liver of DMN mice compared to controls and DMN mice treated with Salvia alone or with Boswellia + Salvia (Table II).

The degree of hepatic inflammation was increased in DMN mice compared to controls, but did not differ between the three groups of DMN mice treated with Boswellia alone, Salvia alone or Boswellia + Salvia (data not shown). Furthermore, in DMN mice not receiving treatment, the serum levels of ALT and AST were higher compared to those in controls and DMN mice treated with Boswellia alone, Salvia alone or Boswellia + Salvia (Table II).

**Immunohistochemical Evaluation**

A marked reduction in \(\alpha\)-SMA and collagen I-III (Figure 5), CTGF and TGF-\(\beta\)1 (Figure 6), as well as Smad3 and Smad7 (Figure 7) staining was observed in the liver of all DMN mice treated with Boswellia plus Salvia compared to the liver of untreated DMN mice. Compared to untreated DMN mice, a clear reduction in all immunostainings was also found in the majority of DMN mice treated with Salvia alone, but not in those treated with Boswellia alone (data not shown). Overall, the immunostaining pattern of \(\alpha\)-SMA, collagen I-III, CTGF, TGF-\(\beta\)1, Smad3 and Smad7 in the DMN mice treated with
Boswellia plus Salvia was similar to that in the DMN mice treated with Salvia alone.

The pattern of CD3+ T cells staining was comparable in the three groups of DMN mice treated with Boswellia alone, Salvia alone or Boswellia plus Salvia, but was less intense than that observed in DMN mice not receiving treatment (data not shown).

PCNA and TUNEL staining were both markedly increased in the liver of mice receiving

Figure 3. A-B. Liver weight and liver weight/body weight ratio (%) in the 5 groups of mice. No significant differences were observed between the various groups.

Table II. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), degree of hepatic fibrosis, and hepatic collagen content in untreated dimethylnitrosamine (DMN) mice and in DMN mice treated with Boswellia (B) alone, Salvia (S) alone or with both Boswellia and Salvia.

<table>
<thead>
<tr>
<th></th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>Fibrosis total score</th>
<th>Collagen content (µg/mg total protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n=6)</td>
<td>44.33 ± 19.42</td>
<td>66.83 ± 28.08</td>
<td>0</td>
<td>0.0135 ± 0.0006</td>
</tr>
<tr>
<td>DMN (n=7)</td>
<td>159.71 ± 89.30*</td>
<td>436.71 ± 123.87*</td>
<td>1.85 ± 0.69*</td>
<td>0.0197 ± 0.0018*</td>
</tr>
<tr>
<td>DMN + B (n=7)</td>
<td>60.16 ± 16.79</td>
<td>85.42 ± 23.47</td>
<td>1.42 ± 0.53</td>
<td>0.0186 ± 0.0012</td>
</tr>
<tr>
<td>DMN + S (n=9)</td>
<td>52.50 ± 10.59</td>
<td>80.16 ± 11.40</td>
<td>0.77 ± 0.66</td>
<td>0.0158 ± 0.0007</td>
</tr>
<tr>
<td>DMN+B+S (n=10)</td>
<td>50.16 ± 14.52</td>
<td>78.16 ± 17.47</td>
<td>0.60 ± 0.51</td>
<td>0.0137 ± 0.0011</td>
</tr>
</tbody>
</table>

(n) = Number of mice. *p < 0.05 vs Controls, DMN+B, DMN+S and DMN+B+S; †p < 0.05 vs Controls, DMN+S and DMN+B+S.
Prevention of DMN-induced hepatic fibrosis in mice

DMN, but returned to normal levels of controls following treatment with Boswellia plus Salvia extracts (Figure 8). A similar trend was observed in the mice treated with Salvia extracts alone.

Discussion

The present study demonstrated that the combined oral administration of *Boswellia serrata*
extracts with anti-inflammatory activity and *Salvia Miltiorrhiza* extracts with antifibrotic effects significantly improved the course and macroscopic findings of DMN-induced chronic hepatitis in mice, as well as the degree of hepatic fibrosis and collagen accumulation, compared to the DMN mice treated with Boswellia alone. However, co-treatment of Boswellia plus Salvia extracts did not significantly increase the antifibrotic effect of salvia extracts.

**Figure 6.** Immunohistochemistry O.M. 4X. Immunostaining both of CTGF and TGF-β1 is most prominent in the liver from dimethylnitrosamine (DMN) group of mice compared to controls, which is markedly reduced by the treatment with Boswellia (B) plus Salvia (S) extracts.

**Figure 7.** Immunohistochemistry O.M. 4X. Immunostaining both of Smad3 and Smad7 is less prominent in the dimethylnitrosamine (DMN) mice treated with Boswellia (B) plus Salvia (S) extracts compared to DMN mice without any treatment.
The main mechanisms of action of the extracts of these two botanical plants remain to be defined. The gum resin extracts from *Boswellia serrata* have been reported to have anti-inflammatory and immunomodulatory effects\(^{11,18,41}\). Boswellic acids, ursane type of pentacyclic triterpenes, have been identified as the main biologically active components of Boswellia extracts\(^{11}\). Boswellic acids suppress the synthesis of the leukotrienes by inhibition of 5-lipoxygenase\(^{41}\), and decrease, in a dose-dependent manner, the recruitment of adherent leukocytes and platelets in the inflamed tissue, primarily by preventing the upregulation of adhesion molecules\(^{32,42}\). In addition, Boswellic acids inhibit leucocyte elastase\(^{43}\) and lipopolysaccharide-induced nitric oxide production\(^{44}\) and suppress the nuclear factor κB (NFkB) and NFkB-regulated gene expression\(^{45}\). Boswellic acids also possess anti-complement activity\(^{46}\). In clinical trials, promising results have been observed in patients with rheumatoid arthritis, ulcerative colitis, Crohn’s disease, and bronchial asthma\(^{9,11,32,47-49}\).

*Salvia Miltiorrhiza* extracts have been widely used in the treatment of cardiovascular and cerebrovascular diseases as well as diabetic nephropathy, arthritis and hepatitis\(^{12-16,19,23,50-52}\). Both the aqueous and lipid soluble fractions of Salvia contain active components with important pharmacological effects being observed in basic experiments and in clinical studies\(^{12-16,53}\). More than 30 diterpene compounds have been separated and identified from Salvia, the most active and structurally representative of the tanshinones of *Salvia Miltiorrhiza*. Tanshinone IIA, a lipophilic compound, is the most abundant and structurally representative of the tanshinones of *Salvia Miltiorrhiza*. Tanshinone IIA has anti-oxidant properties and protects against lipid peroxidation *in vitro* and *in vivo* thus making it a potential antidote for free radical-based disorders\(^{54-57}\). In addition, it appears to possess immunoregulatory effects by inhibiting the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-12, TNFα, INFγ)\(^{58-60}\). Beside these anti-inflammatory activities, tanshinone IIA has displayed a potent antifibrotic effects in several organs including the liver\(^{15,16,19,20,53,60}\). Nevertheless, to date, little is known about the cellular and molecular mechanisms of tanshinone IIA-mediated anti-fibrotic effects in chronic hepatitis. Albeit, several experimental studies have confirmed the effectiveness of salvia extracts in the prevention and treatment of hepatic fibrosis, but, in general, the effects of specific compounds were not evaluated or assessed only *in vitro* studies\(^{13,14,19,23,61-65}\).
Hepatic fibrosis is a common characteristic of chronic liver diseases, which is related to the abnormal accumulation of fibrillar ECM proteins. Fibrosis is a chronic and progressive process acting through complex cell/matrix/cytokine and growth factor interactions, but may be a reversible event. As a result of chronic tissue damage, ECM-producing cells undergo a process of activation characterized by proliferation, motility, contractility, and synthesis of ECM proteins. ECM-producing cells, namely activated hepatic myofibroblasts, may derive from different cell types, such as fibroblasts and myofibroblasts of the portal tracts, biliary epithelial cells and hepatocytes, bone marrow stem cells, and mainly from HSCs. During an inflammatory process HSCs become phenotypically like a myofibroblast acquiring proliferation, mobility and contractility properties. Once the trans-differentiation process starts, transformed myofibroblasts are capable of autocrine stimulation due not only to a variety of secreted mediators but also to the expression of surface receptors. Myofibroblast activation may, therefore, become progressive and be independent of inflammation suggesting that inflammation is a necessary event to start the fibrotic response even if it plays a minor role in the progression of the disease. The fact that fibrosis, in the various organs, does not respond to anti-inflammatory drugs, would appear to confirm the hypothesis that inflammation is not a key process in the pathogenesis and progression of the disease. In the present study, the administration of anti-inflammatory Boswellia extracts alone did not prevent the development of hepatic fibrosis.

Activation of ECM-producing cells is regulated by several soluble factors, including cytokines, chemokines, growth factors, and products of oxidative stress. Of these molecules, TGF-β appears to play a pivotal role. TGF-β is a member of a large family of pleiotrophic cytokines that includes bone morphogenetic proteins (BMPs), activins and other related factors. Three different isoforms of TGF-β (β1, β2, β3) have been found in mammals; TGF-β1 is the most extensively studied and would appear to be the most fibrogenetic. The TGF-β intracellular signal transduction pathway is mediated mainly by Smad proteins.

Smads are a family of 8 related proteins which function as signalling intermediates for the TGF-β superfamily members. Upon ligand binding and activation of TGF-β receptors (I, II, and III), phosphorylated Smad2 and 3 bind with the common mediator Smad4. The Smad 2/3- Smad4 complex translocates into the nucleus where it regulates specific TGF-β target genes. The inhibitory Smad7 antagonizes TGF-β signalling by competing with ligation of Smad2/3 to the activated receptor complex Smad4. Specifically, the target genes known to contain Smad-responsive regions and that are directly or indirectly involved in fibrogenesis, include several fibrillar ECM proteins (collagen, fibronectin), matrix-degrading enzymes (MMPs) and some specific inhibitors (plasminogen activator inhibitor type 1, TIMP-1), as well as genes regulating epithelial-mesenchymal cell transition, proliferation (cyclin-dependent kinase inhibitor p21) and apoptosis (caspases). Furthermore, TGF-β stimulates the synthesis of CTGF, a potent enhancer of myofibroblast proliferation, ECM production and TGF-β self-induction. Disruption of the TGF-β/Smads signalling pathway, either through the loss of Smad3 or the increase of Smad7 expression, confers resistance to tissue fibrosis in several organs including skin, kidney, liver, lung and the cardiovascular system.

Hepatic fibrosis is considered a chronic progressive, dynamic and potentially reversible process. An important goal of research would be to identify anti-fibrotic agents capable to inhibit either the accumulation of activated EMC-producing cells or their pro-fibrogenic action, or capable to stimulate the degradation of ECM. In this study, the prophylactic combined oral administration of Boswellia serrata and Salvia Miltiorrhiza extracts prevented the development and progression of hepatic fibrosis in DMN-induced chronic hepatitis in mice, which appears to be related to the inhibition in the hepatic expression of α-SMA, collagen I-III, CTGF, TGF-β1, and Smad3. These findings were also observed when the DMN mice were treated with Salvia alone, confirming data of previous studies. The rescue effects of either Boswellia or Salvia on established hepatic fibrosis was not evaluated. Nevertheless, the therapeutic anti-fibrotic effect, on established chronic hepatitis, has been reported elsewhere by other Authors. The inhibition of the TGF-β1/Smad3 pathway appears to be linked to the action of Salvia extracts and could be responsible for the reduced activation of the myo-
of myofibroblasts, as indicated by the concomitant reduction in the expression of α-SMA, a marker of the activated myofibroblast phenotype. We did not assess, at which level (transcriptional or posttranslational), the TGF-β1/Smad3 pathway was affected by the treatment. However, inhibition of the TGF-β1/Smad3 pathway reduces the synthesis of CTGF, a potent stimulator of myofibroblast proliferation and ECM proteins production, as well as of TGF-β autoinduction. TGF-β autoinduction is thought to be an important aspect in the maintenance of the fibrotic process over time. On the other hand, the reduction of Smad7 observed in the DMN mice treated with Boswellia plus Salvia is in contrast with the observation that an increase in Smad7 expression confers resistance to tissue fibrosis. The reason for these discrepancies is not clear since the mechanisms regulating Smad7 expression remain to be fully elucidated. Smad7 is strongly and rapidly induced by TGF-β itself. The properties of Salvia extracts in modulating the TGFβ/Smads pathway, as well as the expression of α-SMA and CTGF have been described in several studies.

Besides the TGF-β/Smad pathway, myofibroblasts also appear to play a role in liver fibrosis through the action of other fibrogenetic molecules, such as interleukin-1β, interleukin-6, interleukin-13, insulin-like growth factor-1 (IGF-1), TNF-α, CTGF, platelet-derived growth factor, basic fibroblast growth factor, angiotensin converting enzyme, angiotensin II, vascular endothelial growth factor, endothelin-1, and peroxisome proliferator-activated receptor-γ, which seem to interact directly with Smad3 or their activities are Smad3-dependent. Several observations suggest that tanshinone IIA can attenuate tissue fibrosis by reducing angiotensin II-, IL-1β-, IL-6-, and TNF-α-induced collagen expression. Furthermore, tanshinone IIA possesses antioxidant action by inhibiting the intracellular generation of ROS which play an important role in hepatic fibrosis. These cytokines and ROS were not evaluated in the present study. Salvia miltiorrhiza extracts may ameliorate hepatocytes oxidative damage and attenuate HSCs activation, potentially conferring hepatoprotective and anti-fibrotic effects.

Conclusions

Combined treatment with Boswellia serrata and Salvia miltiorrhiza extracts prevents the development of hepatic fibrosis in an experimental model of DMN-induced chronic hepatitis in mice. The anti-fibrotic properties are mainly related to Salvia extracts and appear to be related, in part, to their effects on the modulation of the TGFβ/Smads signalling pathway in the activated myofibroblasts. Long-term studies in chronic hepatitis-associated fibrosis, both in animal models and in human, are needed to establish the safety and clinical potentials of this anti-fibrotic treatment.

Acknowledgements

This work was supported by a grant from the University of L’Aquila, L’Aquila, Italy. Authors are grateful to Mrs Marian Shields for help in editing the manuscript.

References

6) REEVES HL, FRIEDMAN SL. Activation of hepatic stellate cells—a key issue in liver fibrosis. Front Biosci 2002; 7: d808-826.


Prevention of DMN-induced hepatic fibrosis in mice


80) Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85: 47-64.


